Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. Issue 2 (June 2020)

• Record Type: Journal Article
• Authors: Corsi, D.; Walsh, L.; Weiss, D.; Hsu, H.; El-Chaar, D.; Hawken, S.; Fell, D.; Walker, M.
• Is Part Of: Obstetric anesthesia digest. Volume 40:Issue 2(2020)
• Publication Date: 2020-06
• Subjects: Drug Abuse in Pregnancy -- Maternal Morbidity and Mortality -- Neonatal Morbidity and Mortality; Anesthesia in obstetrics -- Periodicals; Anesthesia in obstetrics -- Abstracts -- Periodicals; 617.968205
• DOI: 10.1097/01.aoa.0000661352.00928.f0
• Languages: English
• ISSNs: 0275-665X

Abstract

Abstract : ( JAMA . 2019;322:145–152) The rate of cannabis use among pregnant women in Canada was 2% in 2017. With recent legalization, it is anticipated that cannabis use among pregnant women will continue to rise. Cannabinoids can cross the placenta and enter the fetal blood supply. Previous studies have demonstrated a relationship between pregnant mothers who use cannabinoids and increased incidence of low birth weight, small for gestational age (SGA), stillbirth, and admission to neonatal intensive care. The aim of this study was to evaluate associations between reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes.